Drug
Maridebart cafraglutide clinical trials
Also written AMG 133.
- studies test it
- 30
- open now
- 8
- in phase 3
- 12
- first study started
- 2020
Keep track of what changes. Save the maridebart cafraglutide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
30 studies that test it; most in 2025 (14)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 5 |
| 2025 | 14 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 15
- Phase 2
- 3
- Phase 3
- 12
What it is tested for
Each study’s main condition, where its own words name it.
- Obesity
- 21
Who runs them
Industry 30 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses maridebart cafraglutide is read from its arms, and is right about nine times in ten.
Testing it · 30
- Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)RecruitingPhase 3AmgenNCT07575399Written as Maridebart Cafraglutide
- Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or OverweightNot yet recruitingPhase 3AmgenNCT07871409Written as Maridebart cafraglutide
- Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 DiabetesNot yet recruitingPhase 3AmgenNCT07866066Written as Maridebart cafraglutide
- Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityRecruitingPhase 3AmgenNCT07037433Written as Maridebart Cafraglutide
- Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)RecruitingPhase 3AmgenNCT07684235Written as Maridebart cafraglutide
- Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)RecruitingPhase 3AmgenNCT07684144Written as Maridebart Cafraglutide
- Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous DoseNot yet recruitingPhase 1AmgenNCT07832799Written as Maridebart Cafraglutide
- Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityRecruitingPhase 3AmgenNCT07037459Written as Maridebart cafraglutide
- A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or ObesityCompletedPhase 1AmgenNCT07310563Written as AMG 133
- Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyActive, not recruitingPhase 3AmgenNCT07225686Written as Maridebart cafraglutide
- Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) TherapyActive, not recruitingPhase 3AmgenNCT07226765Written as Maridebart cafraglutide
- A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or OverweightActive, not recruitingPhase 2AmgenNCT07441252Written as Maridebart cafraglutide
- Effect of Maridebart Cafraglutide on the Heart's Electrical ActivityCompletedPhase 1AmgenNCT07229157Written as Maridebart Cafraglutide
- Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightActive, not recruitingPhase 3AmgenNCT06858839Written as Maridebart Cafraglutide
- A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)Active, not recruitingPhase 2AmgenNCT06660173Written as Maridebart Cafraglutide
- A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous PresentationsCompletedPhase 1AmgenNCT07313761Written as Maridebart Cafraglutide
- A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or ObesityCompletedPhase 1AmgenNCT07717814Written as AMG 133 (frozen liquid)
- Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or ObesityActive, not recruitingPhase 1AmgenNCT07523711Written as Maridebart Cafraglutide
- Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) PresentationsCompletedPhase 1AmgenNCT07226778Written as Maridebart Cafraglutide
- A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes MellitusActive, not recruitingPhase 1AmgenNCT07160257Written as Maridebart cafraglutide
Codes
What other systems call maridebart cafraglutide · ClinicalTrials.gg INT018641
- UNII (FDA) Z24U3U73HNMARIDEBART CAFRAGLUTIDEOne source FDA
- NCI Thesaurus C199209Maridebart CafraglutideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Z24U3U73HN | MARIDEBART CAFRAGLUTIDE | One source FDA |
| NCI Thesaurus | C199209 | Maridebart Cafraglutide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.